Loading...
Please wait, while we are loading the content...
Escitalopram attenuates β-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway.
| Content Provider | Europe PMC |
|---|---|
| Author | Wang, Yan-Juan Ren, Qing-Guo Gong, Wei-Gang Wu, Di Tang, Xiang Li, Xiao-Li Wu, Fang-Fang Bai, Feng Xu, Lin Zhang, Zhi-Jun |
| Copyright Year | 2016 |
| Abstract | Tau hyperphosphorylation is an important pathological feature of Alzheimer's disease (AD). To investigate whether escitalopram could inhibit amyloid-β (Aβ)-induced tau hyperphosphorylation and the underlying mechanisms, we treated the rat primary hippocampal neurons with Aβ1-42 and examined the effect of escitalopram on tau hyperphosphorylation. Results showed that escitalopram decreased Aβ1–42-induced tau hyperphosphorylation. In addition, escitalopram activated the Akt/GSK-3β pathway, and the PI3K inhibitor LY294002 blocked the attenuation of tau hyperphosphorylation induced by escitalopram. Moreover, the 5-HT1A receptor agonist 8-OH-DPAT also activated the Akt/GSK-3β pathway and decreased Aβ1-42-induced tau hyperphosphorylation. Furthermore, the 5-HT1A receptor antagonist WAY-100635 blocked the activation of Akt/GSK-3β pathway and the attenuation of tau hyperphosphorylation induced by escitalopram. Finally, escitalopram improved Aβ1–42 induced impairment of neurite outgrowth and spine density, and reversed Aβ1–42 induced reduction of synaptic proteins. Our results demonstrated that escitalopram attenuated Aβ1–42-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway. |
| Journal | Oncotarget |
| Volume Number | 7 |
| PubMed Central reference number | PMC4924645 |
| Issue Number | 12 |
| PubMed reference number | 26950279 |
| e-ISSN | 19492553 |
| DOI | 10.18632/oncotarget.7798 |
| Language | English |
| Publisher | Impact Journals LLC |
| Publisher Date | 2016-03-01 |
| Access Restriction | Open |
| Rights License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright: © 2016 Wang et al. |
| Subject Keyword | Alzheimer's disease tau protein escitalopram Akt/GSK-3β pathway 5-HT1A receptor Gerotarget |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |